Candida antibodies (IgG, IgA, IgM)

ND-recommended test reviewed: Candida antibodies (IgG, IgA, IgM).
Indications reviewed: fatigue, bloating, brain fog attributed to 'candida overgrowth'; not a validated indication.
Not ordered. Rationale discussed: candida antibodies are common in healthy people; randomized trial found no benefit of antifungal treatment over placebo for the corresponding syndrome. Ref: Dismukes et al 1990, NEJM.
Patient informed test available privately via ND. Patient given info page: https://labs.ajaxharwoodclinic.com/candida-antibodies/patient
Revisit if: a specific, treatable cause of the symptoms is found, or signs of invasive fungal infection in an immunocompromised patient appear.

Indicated when

None recorded.

Not indicated when

• —Ordering Candida IgG/IgA/IgM antibodies to diagnose 'candida overgrowth', 'chronic candidiasis', or 'candidiasis hypersensitivity syndrome' as an explanation for fatigue, bloating, brain fog, or other nonspecific symptoms

Why not

Candida albicans is a normal, common gut and mucosal organism, and antibodies to it are common in healthy people, so a positive result does not by itself indicate disease. The clinical entity this test is usually ordered to support, a chronic 'candidiasis hypersensitivity syndrome' causing fatigue, GI symptoms, and mood changes, was tested directly in a randomized, double-blind trial of long-term antifungal (nystatin) therapy, which found that 'nystatin does not reduce systemic or psychological symptoms significantly more than placebo,' leading the authors to conclude that long-term antifungal therapy for the syndrome 'appears to be unwarranted' [1].

Better first step

Investigate fatigue, GI symptoms, or other nonspecific complaints on their own merits (thyroid disease, anemia, sleep disorders, depression/anxiety, celiac disease, IBS) rather than attributing them to candida overgrowth. Candida antibody and antigen testing does have an established, different role in specialist settings for suspected invasive or disseminated candidiasis in immunocompromised or critically ill patients; that is a distinct clinical situation from the ND-office indication this record covers.

Typical ND rationale

An ND may order Candida IgG/IgA/IgM antibodies in a patient with fatigue, bloating, brain fog, or recurrent yeast symptoms, reasoning that chronic overgrowth of candida in the gut is driving these symptoms, and that antibody testing can confirm it and guide antifungal or dietary treatment.

Ontario coverage & CONO orderability

OHIP status

unverified

Candida antibodies (IgM, IgG, IgA) do not appear by name in the 2026 Schedule of Benefits for Laboratory Services (searched in full for 'candida'), so billing status if a physician ordered this for the outpatient 'overgrowth' indication is unverified. ND-ordered testing is privately paid regardless (Reg. 552 s.22(1)).

CONO orderable

Yes — CONO list #35

CONO 35 'Candida Antibodies (IgM, IgG, IgA)', blood specimen.

Linked conditions

• dysbiosis ↗

Counselling script

“Candida antibody testing isn't something I'd order for these symptoms, because everyone has some candida in their gut and some antibodies to it, so a positive result doesn't tell us it's the cause. When this was actually tested in a clinical trial, long-term antifungal treatment didn't work better than placebo for these symptoms. I'd rather look at the well-established causes of what you're describing.”

Revisit if

• —A specific, treatable cause of the symptoms is identified on further work-up
• —Signs of invasive or disseminated fungal infection in an immunocompromised or critically ill patient (a distinct, specialist-directed situation)

References

1. [1]New England Journal of Medicine (Dismukes et al.) (1990). A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome. linkolder guidelineRCT: nystatin did not reduce systemic or psychological symptoms of 'candidiasis hypersensitivity syndrome' more than placebo; long-term antifungal therapy for the syndrome is unwarranted
2. [2]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkCommunity lab tests are insured only when ordered under the Schedule by an authorized prescriber
3. [3]Government of Ontario (e-Laws) (2026). Health Insurance Act, R.R.O. 1990, Reg. 552: General, s. 22 (insured laboratory services). linkInsured lab testing requires ordering by an authorized provider who has clinically assessed the patient
4. [4]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkTests ordered by anyone other than an authorized provider, including NDs, are not insured services